| |
 |
|
TESTS PER KIT: The kit has the capacity for 20 injections.
SHELF LIFE: The shelf life of the kit is 12 months at -20ºC before RNAi agent is added to the vial and 3 months at -80ºC once the RNAi agent has been added to the vial.
Selected References:
De Vito C, et al. (2011) Let-7a Is a Direct EWS-FLI-1 Target Implicated in Ewing’s Sarcoma Development. PLoS ONE 6(8): e23592. doi:10.1371/journal.pone.0023592
De Vito C, et al. (2012) A TARBP2-Dependent miRNA Expression Profile Underlies Cancer Stem Cell Properties and Provides Candidate Therapeutic Reagents in Ewing Sarcoma. Cancer Cell. DOI 10.1016/j.ccr.2012.04.023.
Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, et al. (2012) Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization. PLoS ONE 7(12): e52397. doi:10.1371/journal.pone.0052397
Liu, C. et al. (January 16, 2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nature Medicine doi:10.1038/nm.2284 Letter.
Luna C, Li G, Huang J, Qiu J, Wu J, et al. (2012) Regulation of Trabecular Meshwork Cell Contraction and Intraocular Pressure by miR-200c. PLoS ONE 7(12): e51688. doi:10.1371/journal.pone.0051688
Sun, CY., She XM., et al. (Oct 26, 2012) miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis.
Trang, P. et al. (March 22, 2011) Systemic Delivery of Tumor Suppressor microRNA Mimics Using a Neutral Lipid Emulsion Inhibits Lung Tumors in Mice. Molecular Therapy doi:10.1038/mt.2011.48
Wang, L. et al. (2012) Loss of miR-29 in Myoblasts Contributes to Dystrophic Muscle Pathogenesis. Molecular Therapy doi:10.1038/mt.2012.35
Wiggins, J.F. et al. (July 15, 2010) Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34. Cancer Res. 70:5923-5930.
|
|
 |
|
|